
Charles E Arber

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7058085/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Knockdown of Amyloid Precursor Protein: Biological Consequences and Clinical Opportunities. Frontiers in Neuroscience, 2022, 16, 835645.	2.8	10
2	Elevated 4Râ€ŧau in astrocytes from asymptomatic carriers of the <i>MAPT</i> 10+16 intronic mutation. Journal of Cellular and Molecular Medicine, 2022, 26, 1327-1331.	3.6	6
3	Mass spectrometry analysis of tau and amyloidâ€beta in iPSCâ€derived models of Alzheimer's disease and dementia. Journal of Neurochemistry, 2021, 159, 305-317.	3.9	8
4	Plasma amyloid-β ratios in autosomal dominant Alzheimer's disease: the influence of genotype. Brain, 2021, 144, 2964-2970.	7.6	16
5	Abrogation of LRRK2 dependent Rab10 phosphorylation with TLR4 activation and alterations in evoked cytokine release in immune cells. Neurochemistry International, 2021, 147, 105070.	3.8	18
6	Familial Alzheimer's Disease Mutations in PSEN1 Lead to Premature Human Stem Cell Neurogenesis. Cell Reports, 2021, 34, 108615.	6.4	53
7	Differential Stimulation of Pluripotent Stem Cell-Derived Human Microglia Leads to Exosomal Proteomic Changes Affecting Neurons. Cells, 2021, 10, 2866.	4.1	6
8	Investigating changes in the proteostasis capabilities of iPSCâ€neurons during development and in FTD using iPSCâ€neurons with <i>MAPT</i> mutations. Alzheimer's and Dementia, 2021, 17, e058308.	0.8	1
9	Familial Alzheimer's disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta. Molecular Psychiatry, 2020, 25, 2919-2931.	7.9	99
10	Investigating proteostasis in development and disease using IPSCâ€neurons with MAPT mutations linked to FTD. Alzheimer's and Dementia, 2020, 16, e039336.	0.8	0
11	Premature neuronal differentiation in familial Alzheimer's disease human stem cells in vitro and in postmortem brain tissue. Alzheimer's and Dementia, 2020, 16, e039793.	0.8	0
12	iPSCâ€derived engineered cerebral organoids (enCORs) as in vitro models of tauopathy. Alzheimer's and Dementia, 2020, 16, e039816.	0.8	0
13	Haploinsufficiency of progranulin causes impairments in PINK/PARKIN mitophagy. Alzheimer's and Dementia, 2020, 16, e042104.	0.8	0
14	Amyloid precursor protein processing in human neurons with an allelic series of the PSEN1 intron 4 deletion mutation and total presenilin-1 knockout. Brain Communications, 2019, 1, fcz024.	3.3	13
15	Susceptibility of brain atrophy to <i>TRIB3</i> in Alzheimer's disease, evidence from functional prioritization in imaging genetics. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 3162-3167.	7.1	41
16	Amyloid β peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 311-321.	2.4	21
17	P1â€188: MODELLING AMYLOID BETA PROFILES IN IPSCâ€DERIVED CORTICAL NEURONS OF MULTIPLE FAMILIAL ALZHEIMER'S DISEASE GENOTYPES, INCLUDING A CASE STUDY OF SAME DONOR CULTURE MEDIA, CSF AND BRAIN TISSUE. Alzheimer's and Dementia, 2018, 14, P350.	0.8	0
18	Human Induced Pluripotent Stem Cell-Derived Microglia-Like Cells Harboring TREM2 Missense Mutations Show Specific Deficits in Phagocytosis, Cell Reports, 2018, 24, 2300-2311	6.4	118

CHARLES E ARBER

#	Article	IF	CITATIONS
19	Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology. Brain Research, 2018, 1701, 75-84.	2.2	25
20	Stem cell models of Alzheimer's disease: progress and challenges. Alzheimer's Research and Therapy, 2017, 9, 42.	6.2	112
21	Mutations in valosin-containing protein (VCP) decrease ADP/ATP translocation across the mitochondrial membrane and impair energy metabolism in human neurons. Journal of Biological Chemistry, 2017, 292, 8907-8917.	3.4	27
22	[P1–219]: PROBING DEVELOPMENTAL CONSEQUENCES OF PSEN1 MUTATIONS IN IPSC DIFFERENTIATION IN 2 AND 3D. Alzheimer's and Dementia, 2017, 13, P327.	2D 0.8	0
23	[P1–220]: 3D CEREBRAL ORGANOIDS AS IN VITRO MODELS FOR ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P327.	0.8	0
24	[P1–025]: PROBING DEVELOPMENTAL CONSEQUENCES OF PSEN1 MUTATIONS IN IPSC DIFFERENTIATION IN 2 AND 3D. Alzheimer's and Dementia, 2017, 13, P242.	^{2D} 0.8	0
25	[P1–180]: DISTINCT Aβ PRODUCTION IN STEM CELLâ€DERIVED CORTICAL NEURONS FROM PATIENTS WITH F MUTATION. Alzheimer's and Dementia, 2017, 13, P311.	AD 0.8	0
26	iPSC-derived neuronal models of PANK2-associated neurodegeneration reveal mitochondrial dysfunction contributing to early disease. PLoS ONE, 2017, 12, e0184104.	2.5	39
27	Review: Insights into molecular mechanisms of disease in neurodegeneration with brain iron accumulation: unifying theories. Neuropathology and Applied Neurobiology, 2016, 42, 220-241.	3.2	114
28	Developmental regulation of tau splicing is disrupted in stem cell-derived neurons from frontotemporal dementia patients with the 10 + 16 splice-site mutation in MAPT. Human Molecular Genetics, 2015, 24, 5260-5269.	2.9	116
29	Activin A directs striatal projection neuron differentiation of human pluripotent stem cells. Development (Cambridge), 2015, 142, 1375-1386.	2.5	134
30	Using human induced pluripotent stem cells to model cerebellar disease: Hope and hype. Journal of Neurogenetics, 2015, 29, 95-102.	1.4	10
31	Cortical interneurons from human pluripotent stem cells: prospects for neurological and psychiatric disease. Frontiers in Cellular Neuroscience, 2013, 7, 10.	3.7	24
32	Activin induces cortical interneuron identity and differentiation in embryonic stem cell-derived telencephalic neural precursors. Nature Communications, 2012, 3, 841.	12.8	68
33	Temporally controlled modulation of FGF/ERK signaling directs midbrain dopaminergic neural progenitor fate in mouse and human pluripotent stem cells. Development (Cambridge), 2011, 138, 4363-4374.	2.5	83